Cadrenal Therapeutics, Inc.
CVKD
$1.19
-$0.01-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.43% | 12.17% | 38.50% | 97.26% | 125.35% |
| Depreciation & Amortization | -68.66% | -70.59% | 263.16% | 219.05% | 191.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.08% | -8.26% | 22.81% | 84.68% | 117.25% |
| Operating Income | 19.08% | 8.26% | -22.81% | -84.68% | -117.25% |
| Income Before Tax | 18.17% | 7.36% | -24.28% | -89.08% | -126.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.17% | 7.36% | -24.28% | -89.08% | -126.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.17% | 7.36% | -24.28% | -89.08% | -126.20% |
| EBIT | 19.08% | 8.26% | -22.81% | -84.68% | -117.25% |
| EBITDA | 19.05% | 8.23% | -22.77% | -84.64% | -117.23% |
| EPS Basic | 49.26% | 43.90% | 29.82% | -25.29% | -65.00% |
| Normalized Basic EPS | 49.26% | 43.90% | 29.83% | -25.29% | -65.00% |
| EPS Diluted | 49.26% | 43.90% | 29.82% | -25.29% | -65.00% |
| Normalized Diluted EPS | 49.26% | 43.90% | 29.83% | -25.29% | -65.00% |
| Average Basic Shares Outstanding | 55.95% | 64.49% | 80.68% | 63.04% | 43.81% |
| Average Diluted Shares Outstanding | 55.95% | 64.49% | 80.68% | 63.04% | 43.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |